NOXXON Announces Record Date and Date of Annual General Meeting

BERLIN--()--Regulatory News:

NOXXON Pharma N.V. (Paris: ALNOX) (Alternext Paris: ALNOX), a biotechnology company whose core focus is on improving cancer treatment by targeting the tumor microenvironment, announced today that it will hold its annual general meeting of shareholders (“AGM”) on June 27, 2017 in Amsterdam, the Netherlands.

The 2016 annual accounts including the annual report, a formal notice convening the AGM, the agenda of the AGM, the explanatory notes to the agenda, the instructions to participate and vote at the AGM, and other AGM documents will be available on the company’s website (www.noxxon.com) as soon as possible and no later than 15 days prior to the date of the AGM. These documents will also be available at the company's offices at Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany, for shareholders and persons entitled to attend the meeting who, upon request, will receive a copy free of charge.

The board of directors has decided that it will apply a registration date for the determination of the persons entitled to attend and to vote at the AGM, which date is the 28th day prior to the AGM pursuant to Dutch law. To be eligible to attend and to vote at the AGM, persons must be registered as shareholder in one of the administration records of the intermediaries that are (indirectly) participants in Euroclear France on May 30, 2017 (the “Registration Date”) after all debit and credit entries have been handled as per the Registration Date.

About NOXXON

NOXXON Pharma N.V. is a clinical-stage biopharmaceutical company focused on cancer treatment. NOXXON’s goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy). NOXXON’s Spiegelmer® platform has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with Keytruda® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON is supported by a strong group of leading international investors, including TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, DEWB, NGN and Seventure. NOXXON has its statutory seat in Amsterdam, The Netherlands and its office in Berlin, Germany. Further information can be found at: www.noxxon.com

Disclaimer

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.

Contacts

For more information, please contact:
NOXXON Pharma N.V.
Aram Mangasarian, Ph.D., Chief Executive Officer
+49 (0) 30 726 2470
amangasarian@noxxon.com
or
NewCap
Florent Alba, +33 (0) 1 44 71 98 55
falba@newcap.fr

Contacts

For more information, please contact:
NOXXON Pharma N.V.
Aram Mangasarian, Ph.D., Chief Executive Officer
+49 (0) 30 726 2470
amangasarian@noxxon.com
or
NewCap
Florent Alba, +33 (0) 1 44 71 98 55
falba@newcap.fr